Aspen announces agreement with Johnson & Johnson to manufacture investigational COVID-19 vaccine candidate
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
and its subsidiaries (collectively “Aspen” or “the Group”)
ASPEN ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON TO MANUFACTURE INVESTIGATIONAL
COVID-19 VACCINE CANDIDATE
Aspen is pleased to announce that one of its wholly-owned South African subsidiaries, Pharmacare Limited
(which trades as “Aspen Pharmacare”), has entered into a preliminary agreement with Janssen
Pharmaceuticals, Inc., and Janssen Pharmaceutica NV, two of the Janssen Pharmaceutical Companies of
Johnson & Johnson, for the technical transfer and proposed commercial manufacture of their COVID-19
vaccine candidate, Ad26.COV2-S.
The vaccine candidate is currently undergoing clinical trials. Aspen Pharmacare will perform formulation,
filling and secondary packaging of the vaccine for supply to Johnson & Johnson. This agreement is still
subject to the successful completion of the relevant technology transfer activities and finalisation of certain
commercial manufacturing terms.
Aspen Pharmacare has agreed to provide the necessary capacity required for the manufacture of Johnson
& Johnson’s COVID-19 vaccine candidate at its existing sterile facility in Port Elizabeth, South Africa.
Aspen has invested in excess of R3 billion in the facility containing the high technology equipment and
systems that will be used to manufacture state-of-the-art sterile drugs and vaccines, packaged into vials,
ampoules and pre-filled syringes. The production area where it is intended that the vaccine candidate will
be manufactured has capacity to produce more than 300 million doses per annum. The facility has
accreditation from a range of international regulatory authorities and provides lifesaving medicines to both
the domestic and international markets. It was part of the first flagship investments announced at the
President’s inaugural South African Investment conference.
02 November 2020
Investec Bank Limited
Date: 02-11-2020 09:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.